These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1661268)

  • 1. [Essential thrombocythemia: therapy with anagrelide].
    Mazzucconi MG; Ferrari A; Balduini CL
    Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
    [No Abstract]   [Full Text] [Related]  

  • 2. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
    Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of essential thrombocythemia with anagrelide.
    Chintagumpala MM; Kennedy LL; Steuber CP
    J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of essential thrombocythemia in childhood.
    Scherer S; Ferrari R; Rister M
    Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy.
    Wong RS; Lam LW; Cheng G
    Ann Hematol; 2008 Aug; 87(8):683-4. PubMed ID: 18299832
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
    Tomer A
    Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
    Andersson BS
    Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
    [No Abstract]   [Full Text] [Related]  

  • 11. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine.
    Dziewierz A; Olszanecka A; Wiliński J; Rakowski T; Kleczyński P; Dubiel JS; Dudek D
    Int J Cardiol; 2012 Oct; 160(2):e31-2. PubMed ID: 22406466
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential thrombocythemia in a child: management with anagrelide.
    Chintagumpala MM; Steuber CP; Mahoney DH; Ogden AK; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1991; 13(1):52-6. PubMed ID: 2029080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of anagrelide in childhood essential thrombocythemia.
    Kanai A; Morokawa H; Matsuda K; Shimazaki E; Nakazawa Y
    Pediatr Int; 2017 Sep; 59(9):1017-1018. PubMed ID: 28707720
    [No Abstract]   [Full Text] [Related]  

  • 17. Is anagrelide safe during pregnancy?
    Cornet N; Vialard F; Mir O; Berveiller P
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):697-699. PubMed ID: 28866127
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
    Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ
    Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926
    [No Abstract]   [Full Text] [Related]  

  • 19. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
    Gillespie E
    Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
    [No Abstract]   [Full Text] [Related]  

  • 20. Anagrelide and the CALR mutation allele burden in essential thrombocythemia.
    Atkinson E; Bakri M; Hayat A; Langabeer SE
    Exp Oncol; 2018 Jun; 40(2):152-153. PubMed ID: 29949532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.